Role of markers of inflammation and endothelial dysfunction in the prognosis of the development of cardiovascular complications in patients with coronary artery disease and metabolic syndrome after coronary stenting

Aim To study the role of inflammation markers and endothelial dysfunction in predicting the risk of cardiovascular event following a percutaneous coronary intervention (PCI) in patients with ischemic heart disease (IHD) and metabolic syndrome (MS).
Materials and methods 80 patients (72 men; median age, 56 (50;63) years) with IHD and PCI were evaluated. Based on the presence of MS according to NCEP-ATP III criteria, patients were divided into two groups, group 1 without MS (n=32) and group 2 with MS (n=48). The control age- and sex-matched group included 15 people without cardiovascular diseases. Serum concentrations of tumor necrosis factor α (TNFα), interleukin 6 (IL-6), IL-10, lipoprotein-associated phospholipase A2 (LP-PLA2), and endothelin 1 were measured by enzyme-linked immunosorbent assay (ELISA). Patients were followed up for 12 months after PCI with evaluation of the incidence of adverse cardiovascular events. Statistical analysis was performed with Statistica 10.0 and Medcalc 19.2.6 software. Differences between variables were considered statistically significant at р<0.05. Potential predictors were determined by the ROC analysis with construction of ROC curves, calculation of AUC (area under the curve), identification of COP (cut-off point by the Youden’s index), and sensitivity (Se) and specificity corresponding to the COP.
Results Patients with MS had statistically significantly higher serum levels of inflammatory markers than patients of the control group. Concentration of the intravascular inflammation marker, PL-PLA2, was 2.7 times higher in group 1 and 5.1 times higher in group 2 than in the control group (р<0.001). Concentrations of endothelin 1 were 1.9 times higher in group 1 and 3.7 times higher in the MS group compared to the control. At one year after PCI, the incidence of adverse outcomes in the form of cardiovascular events was higher for patients with MS: 10 (20.8 %) cases of stent restenosis and 13 (27.1 %) episodes of coronary atherosclerosis progression according to results of repeated coronarography vs. 2 (6.3%) restenosis cases (χ2–10.853; р=0.002) and 2 (6.3%) episodes of atherosclerosis progression (χ2–23.651; р=0.001) for patients without MS. The groups did not differ in rates of myocardial infarction and cardiac death. The most significant predictors of unfavorable prognosis were LP-PLA2 concentration >983.83 ng/ml (area under the ROC curve, 0.867; sensitivity, 80 %; specificity, 100%; р<0.001) and endothelin 1 overexpression >0.852 fmol/ml (area under the ROC curve, 0.885; sensitivity, 85.5 %; specificity, 83.6 %; р<0.001).
Conclusion Patients with MS were characterized by more pronounced imbalance of pro- and anti-inflammatory factors. Concentrations of LP-PLA2 >983.83 ng/ml and endothelin 1 >0.852 fmol/ml were shown to be predictors of unfavorable prognosis for patients with IHD and MS after PCI with coronary stenting.

1. Benderly M, Sapir B, Kalter-Leibovici O, Zimlichman R. Lipoproteinassociated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease. Biomarkers. 2017;22(3–4):219–24. DOI: 10.3109/1354750X.2016.1171910

2. Osmankulova G.E., Noruzbaeva A.M. Lipoprotein-associated phospholipase A2 in patients with coronary heart disease and metabolic syndrome. Russian Cardiology Bulletin. 2016;11(1):34–7.

3. Huang F, Wang K, Shen J. Lipoprotein‐associated phospholipase A2: The story continues. Medicinal Research Reviews. 2020;40(1):79– 134. DOI: 10.1002/med.21597

4. Kuznetsov V.A., Samoylova E.P., Bessonov I.S., Gultyaeva E.P., Zyryanov I.P., Berdinskikh S.G. et al. Long term results of percutaneous coronary interventions comparing with conservative management in treatment of stable ischemic heart disease patients under real circumstances. Russian Journal of Cardiology. 2016;21(2):7–11. DOI: 10.15829/1560-4071-2016-2-7-11

5. Dorodneva E.F., Isakova D.N., Efanov A.Yu. Role of endothelin-1 in the development of cardiovascular disease in patients with diabetes. Medical science and education in the Urals. 2013;14(1):172–6.

6. Rudakova D.M., Veselovskaya N.G., Chumakova G.A., Osipova E.S. Predictors of coronary atherosclerosis at men with the metabolic syndrome. Complex Issues of Cardiovascular Diseases. 2017;6(3):84– 92. DOI: 10.17802/2306-1278-2017-6-3-84-92

7. Mohamed IN, Ishrat T, Fagan SC, El-Remessy AB. Role of Inflammasome Activation in the Pathophysiology of Vascular Diseases of the Neurovascular Unit. Antioxidants & Redox Signaling. 2015;22(13):1188–206. DOI: 10.1089/ars.2014.6126

8. Buckley CD, Gilroy DW, Serhan CN. Proresolving Lipid Mediators and Mechanisms in the Resolution of Acute Inflammation. Immunity. 2014;40(3):315–27. DOI: 10.1016/j.immuni.2014.02.009

9. Schumann J. Does plasma membrane lipid composition impact the miRNA-mediated regulation of vascular inflammation? Medical Hypotheses. 2016;88:57–9. DOI: 10.1016/j.mehy.2016.01.012

10. Dennis EA, Cao J, Hsu Y-H, Magrioti V, Kokotos G. Phospholipase A 2 Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention. Chemical Reviews. 2011;111(10):6130–85. DOI: 10.1021/cr200085w

11. Teplyakov A.T., Kuznetsova A.V., Protopopova N.V., Andriyanova A.V., Suslova T.E., Nasanova O.N. et al. Lipoprotein-associated phospholipase a2 in cardiovascular risk stratification after coronary angioplasty in patients with type 2 diabetes: which decision rule threshold to choose? Bulletin of Siberian Medicine. 2015;14(2):47–54. DOI: 10.20538/1682-0363-2015-2-47-54

12. Widmer RJ, Lerman A. Endothelial dysfunction and cardiovascular disease. Global Cardiology Science & Practice. 2014;2014(3):291– 308. DOI: 10.5339/gcsp.2014.43

13. Chen J, Chen M-H, Guo Y-L, Zhu C-G, Xu R-X, Dong Q et al. Plasma Big Endothelin-1 Level and the Severity of New-onset Stable Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis. 2015;22(2):126–35. DOI: 10.5551/jat.26401

14. Zhou B-Y, Guo Y-L, Wu N-Q, Zhu C-G, Gao Y, Qing P et al. Plasma big endothelin-1 levels at admission and future cardiovascular outcomes: A cohort study in patients with stable coronary artery disease. International Journal of Cardiology. 2017;230:76–9. DOI: 10.1016/j.ijcard.2016.12.082

15. Aflyatumova G.N., Sadykova D.I., Nigmatullina R.R., Chibireva M.D. Endothelial dysfunction in essential hypertension in adolescents (clinical and experimental study). Arterial Hypertension. 2017;23(2):131–40. DOI: 10.18705/1607-419X-2017-23-2-131-140

16. Gottlieb SS, Harris K, Todd J, Estis J, Christenson RH, Torres V et al. Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. Clinical Biochemistry. 2015;48(4–5):292–6. DOI: 10.1016/j.clinbiochem.2014.12.012

17. Berns S.A., Schmidt E.A., Yukhno E.S., Nagirnyak O.A., Khomyakova T.A., Barbarash O.L. The effect of endothelial dysfunction on prognosis in patients with acute coronary syndrome without ST segment elevation. Kardiologiia. 2015;55(4):14–8.

18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486– 97. DOI: 10.1001/jama.285.19.2486

19. Teplyakov A.T., Bolotskaya L.A., Vdovina T.V., Stepachesa T.A., Kuznetsova A.V., Maslov A.P. et al. Clinical and immunomodulatory effects of polyoxidonium for the correction of secondary immunodeficiency in patients with coronary heart disease associated with type 2 diabetes. Immunology. 2008;29(1):44– 51.

20. Liu H, Yao Y, Wang Y, Ji L, Zhu K, Hu H et al. Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: a cross-sectional study. Journal of Cellular and Molecular Medicine. 2018;22(10):5145–50. DOI: 10.1111/jcmm.13803

21. Ge P-C, Chen Z-H, Pan R-Y, Ding X-Q, Liu J-Y, Jia Q-W et al. Synergistic Effect of Lipoprotein-Associated Phospholipase A2 with Classical Risk Factors on Coronary Heart Disease: A Multi-Ethnic Study in China. Cellular Physiology and Biochemistry. 2016;40(5):953–68. DOI: 10.1159/000453153

22. Huang Y, Wu Y, Yang Y, Li W, Lu J, Hu Y. Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China. Scientific Reports. 2017;7(1):16092. DOI: 10.1038/s41598-017-16464-5

23. Benderly M, Sapir B, Kalter-Leibovici O, Zimlichman R. Lipoproteinassociated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease. Biomarkers. 2017;22(3–4):219–24. DOI: 10.3109/1354750X.2016.1171910

24. Huang F, Wang K, Shen J. Lipoprotein‐associated phospholipase A2: The story continues. Medicinal Research Reviews. 2020;40(1):79– 134. DOI: 10.1002/med.21597

25. Dorodneva E.F., Isakova D.N., Efanov A.Yu. Role of endothelin-1 in the development of cardiovascular disease in patients with diabetes. Medical science and education in the Urals. 2013;14(1):172–6.